Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.

Antipsychotic treatment maintenance reduces risk of relapse in FEP patients

6 days ago

Patients with first-episode psychosis (FEP) may benefit from continuing their antipsychotic treatment, with a recent study showing that treatment maintenance protects against relapse risk, whereas discontinuation for 2 months increases the risk.

Researchers performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing FEP relapse rates between antipsychotic treatment discontinuation and maintenance groups at 1, 2, 3, 6, 9, 12 (primary), and 18–24 months.

A total of 10 RCTs, involving 776 FEP patients with a mean study duration of 18.6 months, were included. Of these, four RCTs had the antipsychotics discontinued abruptly. The remaining six RCTs had treatment ceased after tapering off gradually over several months.

Relapses occurred with significantly greater frequency in the discontinuation group than in the maintenance group. This was true at all time points except at 1 month (2 months: risk ratio [RR], 0.49; 3 months: RR, 0.46; 6 months: RR, 0.55; 9 months: RR, 0.48; 12 months: RR, 0.47; 18–24 months: RR, 0.57).

However, maintenance treatment was associated with a nonsignificant increase in the risk of discontinuation due to adverse events (RR, 2.61).

Although it appears that maintaining antipsychotic treatment is beneficial for preventing relapses for at least 2 years in remitted/stable FEP patients, it remains unclear whether this would be the case for longer than 2 years, researchers said.

There are currently no clinical measures or biomarkers that may facilitate identification of remitted/stable FEP patients who are not at risk of relapse after discontinuation of their antipsychotic treatment, they added. More work is needed to establish these predictive biomarkers to aid in decision-making and a personalized medicine approach.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.